US Pharma MarketingWith many pharma companies focused on developing drugs that shed pounds, Biohaven is digging its heels into a clinical program based on an experimental myostatin inhibitor that builds muscle.
Obesity drugmakers chase weight loss. Biohaven is betting on muscles.
<figure><div><img src="https://imgproxy.divecdn.com/-kkjujWNljE5k9YM1PwRLn7_AtEY9Uh4Fbs4E-ua2rg/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTY4Nzg5NDAxLmpwZw==.webp"/></div></figure><p>With many pharma companies focused on developing drugs that shed pounds, Biohaven is digging its heels into a clinical program based on an experimental myostatin inhibitor that builds muscle. </p>
Source: PharmaVoice